By Fineline Cube Hangzhou Ao’rui Biological Technology Co., Ltd (Oriomics) announced the market launch of XiaoWeiAn, a multi-tumor early screening product targeting liver, gastric, intestinal, esophageal, and pancreatic cancers. The product, a first-in-class multi-omics cancer joint inspection product based on the real-time PCR and chemiluminescence dual platform, boasts 88.4% overall sensitivity, 98.5% specificity, and 83.2% traceable accuracy.
Company Focus and Technology
Oriomics, focused on non-invasive early screening of tumors and accurate diagnosis of cancer, utilizes noninvasive liquid biopsy technology and a two-layer machine learning analysis core algorithm based on big data artificial intelligence analysis. The company develops products for early screening and diagnosis of single cancer and multiple cancers. Beijing Hotgen Biotech Co., Ltd (688068.SH) became its strategic investor in January 2022.-Fineline Info & Tech